Avid Bioservices Inc (CDMO)

[cjgaddy]

Two important facts, about the ongoing n=121 2nd-Line NSCLC Ph.2B trial patient population to keep in mind, as we await Dr. Gerber's Sept 7th Plenary Presentation at the ASCO/ASTRO Thoracic Symposium in Chicago...

7-16-12, VP/ClinAffairs Joe Shan: ”We have also conducted further analyses of the top line results and determined that not only were baseline haracteristics well-balanced across all treatment groups, there are no subgroup differences in geography, age, gender, race, et cetera...."
=> Qtly. Conf. Call http://tinyurl.com/cs7spbz

7-12-12, CEO Steve King: ”They (2nd-Line NSCLC) were Stage IIIB/IV patients. The majority were Stage IV; I believe a little over 90% of the patients in each of the arms were Stage IV.”
=> JMP/NYC http://tinyurl.com/csdclwb